COMMUNIQUÉS West-GlobeNewswire

Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
23/06/2026
Dr. Victor Fontenelle Bastos de Lima, an investigator on Nexalin’s recently completed Brazilian clinical study, received the Young Researcher Award at BRAIN 2026 – Congress on Brain, Behavior and Emotions, held in Porto [...]
Tria Federal Appoints Former CMS and IRS CIO Rajiv Uppal to Advisory Board
23/06/2026
ARLINGTON, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Tria Federal today announced the appointment of Rajiv Uppal, former Chief Information Officer of the Centers for Medicare & Medicaid Services (CMS) and the Internal [...]
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
23/06/2026
REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has [...]
Wesley Pharmaceuticals Expands Longevity Portfolio with Launch of Three Essential Injectable Formulations
23/06/2026
Industry-leading compounding pharmacy introduces Methylcobalamin, Glutathione, and Magnesium Chloride to support cellular energy, metabolic health, and antioxidant defense ORLANDO, Fla., June 23, 2026 (GLOBE NEWSWIRE [...]
SRX Global Makes Strategic Investment in Clinical-Stage Biodefense Company, ARMR Sciences
23/06/2026
NORTH PALM BEACH, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- SRX Global, Inc. (NYSE American: SRXH) (the "Company", or “SRX”) today announced a strategic investment in ARMR Sciences, a clinical-stage biodefense company [...]
Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
23/06/2026
CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion to initiate the [...]
The XLH Network and Kyowa Kirin Launch the XLH Community Guidebook to Help People Navigate Lifelong Journey with XLH
23/06/2026
New online resource brings together practical information, community perspectives, and expert guidance tailored to people with XLH across ages and life stages PRINCETON, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Kyowa [...]
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
23/06/2026
Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectin Company intends to file the Phase 3 protocol in Q3 2026 and is actively [...]
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel
23/06/2026
- First glioblastoma patient ever treated with Alpha DaRT® outside of the United States, and the first in Israel - performed at Hadassah University Medical Center in Jerusalem, one of the world’s premier academic [...]
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
23/06/2026
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading direct-to-patient telehealth company, today announced that its Board of Directors has authorized a cash dividend to holders of the [...]
Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Advancing Nanoparticle-Encapsulated PNKP Inhibitor in Oncology Space
23/06/2026
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within [...]
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
23/06/2026
QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA Pivotal Phase 3 Study Expected to Initiate in the Second [...]
IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification
23/06/2026
On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer Novel immunotherapy [...]
Corxel Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Trial of CX11 in Obese and Overweight U.S. Adults
23/06/2026
U.S. Phase 2 trial met primary endpoints, with up to 11.5% weight loss at 36 weeks, showing continued weight reduction at a consistent rate and no evidence of a slowing trajectory CX11 demonstrated favorable GI [...]
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas
23/06/2026
Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders Lilly and Astellas to serve as “stalking horse” bidders in [...]
CoreHealth Announces Leadership Transition as Charles Martin Appointed Chief Executive Officer
23/06/2026
TORONTO, June 23, 2026 (GLOBE NEWSWIRE) -- CoreHealth Technologies Inc. today announced that Michael Peters will conclude his tenure as Chief Executive Officer at the end of June, following five years of leadership that [...]
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
23/06/2026
Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company [...]
Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System
23/06/2026
Leading academic center with multi-hospital and multi-state health system deepens Company’s footprint in the Northeast U.S. The Company now has multiple accounts and hospitals that have adopted the LIBERTY System across [...]
Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia
23/06/2026
Agreement Marks Company’s Expansion into Precision Oncology Testing, with the Goal of Establishing Malaysia's First Clinically Validated PDO Platform KUALA LUMPUR, Malaysia, June 23, 2026 (GLOBE NEWSWIRE) -- Alps Group [...]

Pages